Aim: To assess the eff ect of the factor 'hepatic metastatic disease' on long-term outcomes in patients with colorectal cancer. Materials and methods: We analysed retrospectively 200 randomly selected patients. Forty-two of them were excluded from the study for diff erent reasons so the study contingent was 158 patients over a period of 23 years. All were diagnosed and treated in the Lozenetz University Hospital, in the Department of General Surgery. 125 of the patients were diagnosed with colorectal cancer without distant metastases and 33 of the patients had liver metastases as a result of colorectal carcinoma. The statistical analysis was performed using SPSS 19 IMB, with a level of signifi cance of P < 0.05 at which the null hypothesis is rejected. We also used descriptive analysis, Kaplan-Meier estimator, Log-Rank Test and LifeTable statistics models. Results: The median survival for patients without metastases was 160 months, and the median was 102 months. The median survival for patients with liver metastases was 28 months and the median was 21 months. One-year survival for patients without metastases was 92% versus 69% in patients with liver metastases. Conclusion: Average, annual and median survivals are infl uenced statistically signifi cantly by the presence of liver metastases compared to overall survival and that of patients without metastatic colorectal cancer. Liver metastatic disease is a proven factor aff ecting long-term prognosis and survival in patients with colorectal cancer.
INTRODUCTION
Metastatic progression of cancer diseases is a major factor affecting survival in patients with neoplastic diseases. 1 Colorectal cancer (CRC) is not an exception in this regard. Given the extremely high frequency which keeps increasing recently and the great many cases of late-diagnosed patients with advanced stage of cancer with distant dissemination, it is absolutely necessary that in-depth research in the treatment of metastatic colorectal cancer be carried out. 2 As the main location of distant metastatic process is the liver, it has become very common in the surgical community to refer to this condition as 'hepatic metastatic disease' (HMD). 3 That requires a thorough examination of the treatment options and outcomes for patients with colorectal cancer and HMD. In recent years, many authors have analyzed a number of factors affecting distant outcomes of patients with colorectal cancer, suggesting that the major ones can be the stage of the disease and the presence of liver metastases. 4 The progress of modern oncology enabled multidisciplinary approach to patients who have HMD with very good long-term results. 5 
AIM
To assess the impact of HMD on long-term outcomes in patients with colorectal cancer.
MATERIALS AND METHODS
The present retrospective study included 200 randomly selected patients. Forty-two of them were excluded because of unspecified metastasis (9 patients) and distant metastasis with various liver localization (33). Between 1990 and 2013 this study recruited 158 patients diagnosed with colorectal cancer and followed them up until 10.03.2014. The median follow-up was 62 months. The data for this clinical study were collected from the National Cancer Registry of the Republic of Bulgaria. The patients were diagnosed and surgically treated at the Lozenetz University Hospital. Of these patients, 125 were diagnosed with colorectal cancer without distant metastases and 33 had colorectal cancer and liver metastases both treated surgically. The statistical analysis was performed using SPSS (IBM). 19 The level of signifi cance was set at 5% (P < 0.05) in all analyses. Descriptive statistical methods were used; the qualitative variables between the groups were compared by χ² test; the quantitative variables were compared by t-test for independent samples, Kaplan-Meier estimator, life tables and log rank analysis. Table 1 presents the main demographic parameters of the two groups of patients -HMD, as a consequence of CRC and non-metastatic CRC. We found no signifi cant differences between the groups in the main demographic characteristics (P > 0.05). Twenty-one of 33 patients with hepatic metastatic colorectal cancer had a single lesion in hemiliver, 4 of the patients had multiple lesions in hemiliver, and 8 of the examined patients had multiple lesions disseminated throughout the liver.
RESULTS
We determined the expected average and median survival presented with standard deviation and 95% confi dence intervals (CI). Using the log-rank test we found that there was a signifi cant difference in the expected average and median survival (P<0.001) between patients with hepatic metastatic disease and non-metastatic CRC. Fig. 1 shows the function of survival comparing the two treatment groups (patients with HMD and non-metastatic colorectal cancer). The median survival in patients without metastasis was 160 ± 15 months, with a confi dence interval CI months and the median was 102 ± 2 with median confi dence interval CI [81-123] months. The median survival in patients with liver metastasis was 28 ± 6 months with a confi dence interval CI months and the median was 21 ± 3 months with a median confi dence interval CI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] months.
In order to determine the year survival rate we used the life-table analysis (Fig. 2) . One-, two-, three-and fi ve-year survival was statistically signifi cantly different between the two groups, P<0.01 for the fi rst, second and third year and P<0.01 for the fi ve-year survival.
DISCUSSION
Colorectal cancer is the most common neoplasm in the digestive system and the second most frequent of all cancers. 6 For its part, HMD is a major factor, Blue "+" -NMCRC ("Censored") Green "+" -HMD ("Censored") associated with survival of patients with colorectal cancer. 1 In the present study, comparing patients with liver metastatic disease (surgically treated) and those without, we found no signifi cant differences in terms of sex, age, body mass index and the presence of co-morbidity. Surgical treatment is still the main pillar in the treatment of HMD. 7 Progress and establishment of various innovative methods for its application in modern oncology refl ects on distant results. 8 In the last 20 years new criteria for resectability of liver lesions have been accepted increasing the volume of resectable liver metastases. 9 This in turn improved the prognosis of patients with end-stage colorectal cancer. 10 In the group of patients with HMD the cases with single liver lesions were predominant. This trend is due to early detection of metastatic process as a result of the progress of diagnostic imaging methods. 11 Most of the patients (92%) in our study underwent liver resection; 23% of these were abnormal liver resections. A large part of them as tumorectomy -10% and 59% -typical liver resections, most often sectorectomy and hemiliverectomy. In recent years, the method of radiofrequency ablation has become a quite often used surgical modality -we applied it only for a few patients with unresectable HMD. 8 Strang and co-authors highlighted a number of advantages in the treatment of unresectable liver metastases with radiofrequency ablation. Operative intervention in the liver is extremely precise, according to the general condition of patients, remaining liver parenchyma and the possibility of radicalism of the intervention. 12 Speaking of distant results, it is appropriate to discuss the results of the total patient population, including patients with liver metastases and without metastases. Their median survival at fi rst glance seems encouraging, but considering that few cases distort the statistical model of survival, median survival rate should be used as a reliable method for determining the prognosis. As for the tested two groups -patients without metastases and those with liver metastases, there is a signifi cant difference in the mean and median survival. On the background of the long follow-up period (23 years) and the fact that many of the patients have undergone treatment different from current chemotherapy, radiotherapy and comparing results to global trend, results show better survival in both groups, as a result to multidisciplinary approach to the oncological disease. 13, 14 Ghazali et al. determined the infl uence of various factors associated with the prognosis of patients with CRC, announcing similar year survival in non-metastatic colorectal cancer stages I-III.
Stage and presence of metastases were identifi ed as independent factors infl uencing the prognosis of patients with colorectal cancer by number of authors such as Ferrand et al. Furthermore, several other factors infl uence the survival rate -both medical (stage, co-morbidity, lymphatic infi ltration, local status, etc.), and social (access to oncology center, personal desire for treatment, etc.). 15, 16 The development of chemotherapy and radiotherapy, and in particular the treatment of HMD also affects the evolution and outcome of the disease. 17, 18 Evaluated by 95% confi dence interval, average and median expected survival were statistically signifi cantly higher in patients with non-metastatic colorectal cancer. This is a valuable method for determining the expected survival for patients which is based on the stage of the disease. 19 Kumar et al. highlight the advantages of the method and defi ne HMD as a major factor infl uencing the prognosis of patients with colorectal cancer. All these results form HMD as a major factor of survival and distant prognosis in patients with colorectal cancer. Proof of this is the conducted Log Rank (Mantel-Cox)-test with a high level of signifi cance determining statistically significant difference between year survival in patients with HMD and those without metastatic process. The difference between the two groups at any interval is statistically signifi cant and determines a better prognosis of patients without metastatic process. 20, 21 Khattak et al. conducted a study based on the Australian Cancer Registry, linked with advanced colorectal cancer and the differences between metastatic and non-metastatic CRC. Using life table analysis they determine the metastatic process as a major factor affecting survival in patients with colorectal cancer. Compared to results from other centers around the world, these are good results for the time of follow-up of the patients. 19, 22 In the fi nal stage, patients with HMD have a relatively better prognosis after a therapeutic treatment. 23 Lordan and co-authors conducted a 10-year follow-up of patients after radical resection of liver with HMD in patients with colorectal cancer, and reported excellent results, better prognosis and improved median survival based on a multidisciplinary approach to the disease. These results set a different attitude, towards patients with liver metastases. Apart from these poor prognosis patients have a higher risk of recurrence, as well as the underlying disease and the HMD. 24, 25 This requires that patients with HMD should be included in a program with inten-sive follow-up, as are the recommendations of the National Board of Oncology. 26 Regular study of tumor markers and implementation of radiological methods provide adequate control of the disease and improve survival. 27 This is especially important for the multidisciplinary approach and therapeutic (surgical, chemotherapy and radiotherapy) behavior in patients with HMD that provides a better longterm prognosis. 28, 29 Langenhoff et al. reported a higher risk of recurrence in patients after radical resection of liver metastases due to colorectal carcinoma and analyze similar measures, necessary to monitor patients after radical treatment of HMD.
CONCLUSIONS
HMD makes the prognosis of patients with colorectal cancer signifi cantly worse. The average and median survival and one-, two-, three-and fi ve-year survival rate are infl uenced on the presence of liver metastases, compared with overall survival of patients without metastatic process. Hepatic metastatic disease is a proven independent factor infl uencing the long-term prognosis in patients with colorectal cancer. Despite the progress of oncology, the prognosis for patients with HMD remains unsatisfactory and requires hard work of surgeons and oncologists, as well as the implementation of early diagnosis and screening for colorectal cancer.
